Winter 2015. This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities.

Winter 2015

This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not strictly historical statements, including, without limitation, statements regarding the plans, objectives and future financial performance of ScripsAmerica, constitute forward-looking statements which involve risks and uncertainties. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including anticipated operating losses, uncertainties associated with research, development, testing and related regulatory approvals, unproven markets, future capital needs and uncertainty of additional financing, competition, uncertainties associated with intellectual property, complex manufacturing, high quality requirements, dependence on third-party manufacturers, suppliers and collaborators, lack of sales and marketing experience, loss of key personnel, uncertainties associated with market acceptance and adequacy of reimbursement, technological change, and government regulation. For a more detailed description of the risk factors associated with the Company, please refer to the Company’s periodic reports filed with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K for the year ended December 31, 2013. Undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to update any forward-looking information contained in this presentation.

Safe Harbor Statement

A leading, vertically integrated provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies Serving large and growing markets:

Specialty Pharmaceuticals & Medical SuppliesRapid Growth, Improving Financial Performance, Projecting Q1 Profits:

Solid Balance Sheet/Minimal Debt ($4MM LOC w/Triumph Healthcare)Exciting growth opportunities:

New ProductsNew GeographiesNew Distributors/Manufacturers

ScripsAmerica, Inc.

2014 (P) 2013 Increase(in millions, except EPS)

Revenues 31.50$ 0.60$ 30.90$

Net (Loss) (1.20)$ (11.30)$ 10.10$

EPS (0.01)$ (0.17)$ 0.16$

Q1 15 (P)

(in millions, except EPS) (3/31/2015)

Revenues $ 9.60

Net Income $ 0.40

EPS $ -

Trading Snapshot

Symbol SCRC

Exchange OTCBB

Price (3/16/15) $0.12

Market Capitalization (3/16/15) ~ $17 MM

52- Week Range $0.08 - $0.22

Average Daily Volume 500,000

Shares Outstanding/Authorized 138MM/250MM

Corporate Headquarters Tysons Corner, Virginia

2008 Founded 2010 Operations Commence 2010 – 2012 Pharmaceutical distribution services (primarily McKesson)

Retail, hospitals, long-term care facilities and government and home care agencies

2013 McKesson squeezes margins, increases chargebacks 2013-2014 ScripsAmerica Pivots to New Growth Strategy

Initial (majority) investment in Main Avenue Pharmacy

New Strategy

oEnter Specialty Pharmacy and Independent Pharmacy distribution marketsoAdding other, complementary products

ScripsAmerica: Evolution of A Healthcare Leader

One Platform – Multiple Opportunities

ScripsAmerica

Wholesale RxMain Avenue

PharmacyEvolving BusinessesPIMD

Diabetic Supplies

RapiMed

E2014 Revenues@$29,000,000.00

February ‘15 Revenues

@$554,000.00

Established Operations Evolving Operations

700+ Patients Signed

$200,000 OrderPending

PhysicianDispensing

Estimated 1% - 5% of population cannot tolerate medications in standard formulas*Specialty pharmacy industry growth drivers:

Shortages of mass-produced drugs Growth in the senior citizen populationIncreased awareness of compounding pharmacies and pharmaceutical applications

Physicians concerned about prescribing narcotic pain medication (e.g. Oxycontin, Vicodin, Hydrocodone) and are looking for alternative delivery systems

Compounding industry:$5 billion in Annual Revenues

“A growing number of doctors and patients will likely turn to compounding pharmacies to prepare medications with alternate doses and strengths”*

*source: IBIS Worldwide

The Specialty Pharmaceuticals Market

Main Avenue Pharmacy acquired Feb. 14, 2014 (100% effective

October 2014) Offering a wide variety of specialty pharmaceutical products to

treat pain, scars, wounds, vitamin deficiencies among others

FDA approved and licensed in 10 states

Additional states being added

Capacity of hundreds of compounding prescriptions/month

In process of expanding

No manufacturing (subject to more restrictive regulations)

ScripsAmerica’s Specialty Pharma Business

Doctor writes prescription

Submitted for payment to Insurance Company/Third party payers

No Medicaid, Medicare

Prescription approved for payment

Order to compound transmitted to Main Avenue Pharmacy

Bill generated & sent to Insurer/3rd Party Payer

Prescription sent FedEx to patient - who must sign return receipt

Total Payment Cycle Time: 35 days

2006

Pre-Approval Avoids Collection Risk

83% reported significant reduction in their pain after using custom-compounded prescription pain creams

On average, survey respondents said the creams reduced their pain levels by more than half Five percent of respondents say the creams completely eliminated their pain 38 % reported reducing other oral pain medications while using the creams > 83 % of respondents said their pain had eased since starting their use of the non-opioid

prescription creams They reported an average reduction of 57 percent in their pain level after directly applying the

creams to the site of their pain, for most recent 24-hour period After 4 weeks, patients reported significant improvement in their physical and emotional quality

of life Six percent of the patients reported minor adverse effects - such as rashes.

Case Study: Just One of ScripsAmerica’s Many Products

• The results demonstrate the ability of locally-applied prescription creams to deliver significant pain relief over time to many patients, without the need for patients to rely on opioids and other narcotics.

• The FDA, quoted in the New York Times, said prescription drugs account for about three-quarters of all drug overdose deaths in the United States, with the number of deaths from narcotic painkillers, or opioids, quadrupling since 1999.

• A 2011 report in the journal Pain Medicine, estimated the total societal cost of prescription opioid abuse at $55.7 billion. 

Source: Patient Outcomes Analytics (POA), a research organization, a survey assessing patients' experience with topical prescription pain creams and their impact on the use of other oral pain medications. POA implemented an Institutional Review

Board (IRB) approved protocol to survey and assess patient outcomes.

More than 100 million Americans suffer from chronic pain

Specialty Pharmaceuticals Growth Strategy

Expand Licensing to New States

Add PharmaciesTwo Pharmacies under LOI - will add 30

states

Bring on Additional Marketing Partners

Introduce New Products

RapiMed – Child Pain & Fever Relief tablets-

Approval Pending

PIMD International

Physician Dispensing Program

Diabetic Medical Supplies

Other Growth Platforms

RapiMed Oral Delivery Technology

Rapid Release, Fast Dissolving Fever & Pain Relief Tablets

Over The Counter Product Manufactured in United States

Regulated dosage (80mg, 160mg) for children 2 – 11

Signed Contract with Distributor in China

$200,000 order pending- $60,000 Cost (Attractive Margins)

Oral Tablet that dissolves in 25-35 Seconds

Fruit Flavors-Wild Cherry, Wild Grape

Fast Absorption Into System

Problem: Small chains/individual pharmacies unable to fill prescriptions for controlled substances

Product manufacturers impose minimum order quantities far beyond the needs of the smaller operations

Solution: A DEA and State licensed business that represents independent pharmacies

PIMD licensed by DEA and 14 states for wholesale distribution of Prescription drugs and OTC branded products

Off to good start Revenues

January 2015 $135,000

February 2015 $554,000

PIMD International, LLC

Physician Dispensing Program

Nearly all States have regulations governing the dispensing of drugs by physiciansTypical Regulations:

Dispensing in limited situationsState agencies licensure Limit profits on drugs dispensed by physicians Protect freedom of choice for consumersProcedural controls - such as labeling and record keeping

ScripsAmerica’s PDP program facilitates Physician ComplianceActively Being Marketed - In Discussion with Several Doctors

Goal = 100 dispensing physicians by 12/31/15

Robert Schneiderman, CEO & Founder

Accomplished entrepreneur with proven track record building businesses and creating value for shareholders

CEO of one of Philadelphia’s leading recruitment firms for 32 years

Jeffrey Andrews, CFO

Finance professional with extensive background creating value with public companies

CFO - Global Resource Corporation, Judge Information Management Solutions, and The Judge Group

Other Key Executives

Peter W. Megill, CPA, Corporate Controller 25 years experience

Chad Beene, National Sales Manager 11 years experience

Adam Brosius, Director Business Development 15 years experience

Strong, Experienced Leadership Team

Financial Results

Recent Results of Operations

Significant Improvement

In millions, except EPS 2014 (P) 2013 Improvement

Net Revenues $ 31.5 $ 0.60 + $ 29.9

Operating Income ($ 0.01) ($ 7.4) + $ 7.4

Net (Loss) ( $ 1.2) $(11.3) + $ 10.1

EPS ($ 0.01) ($ 0.17) + $ 0.16

Shares 127.5 68.1

(P) Preliminary results, subject to final audit

March 31, 2015

(Projected)

March 31, 2014

(Actual)

(3 months) (3 months)

Revenue $ 9,600,000 $ 800,000

Operating Income* $ 1,001,000 $ 612

Income (loss) from Operations $ 594,000 ($ 214,000)

Net Income (loss)** $ 407,000 ($1,213,000)

* prior to shares issued for services** due to NOL, no tax liability recognized

First Quarter 2015Profitable

Strong & Improving Financial PositionDecember 31, 2014* December 31, 2013*

(000’s omitted)

Cash $ 730 $ 47 Receivables $ 2,679 $ 1,089 Inventory $ 1,011 $ - 0 - Total Current Assets $ 4,699 $ 1,490

Total Assets $ 5,659 $ 1,781

Line of Credit $ 653 $ 99 Payables & Accruals $ 2,268 $ 227 Purchase Order Financing $ -0 - $ 1,037 Deferred Revenue $ 225 $ -0 - Total Current Liabilities $ 3,349 $ 3,188

Preferred Stock $ 1,043 $ 1,043

Total Equity/(Deficit) ($ 0.1) ($ 3,617)Total Liabilities & Stockholders Equity $ 5,659 $ 1,781

* BALANCE SHEET EXCERPTS

149 Shareholders of record ~ 50% owned by 10 "Friends & Family" Shareholders Preferred Convertible Debt

- $1MM-Held by Board Member, Convertible into 6MM shares Term Debt – $233,000, 9% due 9/2016. Holder: Board member Convertible Debt: $616,000 convertible at $.175 Unsecured Debt $300,000 due 12/2015 A/R Financing of $4,000,000 (Secured) Rapidly decreasing high-cost debt Significant tax loss carryforwards available

Capital Structure 12/31/14 12/31/13

Working Capital $1.350 MM ($1.698 MM)

ScripsAmerica – Summary

Expand the Compounding Rx Business-Add new Pharmacies, Products and Formulations

Launch RapiMeds Launch Physician Dispensing Program Add New Formulations of the Oral Delivery Technology Strategic Acquisitions Eliminate Convertible Notes/Pay Off Unsecured Debt Uplist to Major Exchange

ScripsAmerica – Strategy

Valuation*

2014Multiple of (e) sales @0.60X

*as of 3/13/15

www.scripsamerica.com

Robert Schneiderman, CEO800-957-7622 ext 101

[email protected]

Jeffrey J. Andrews, CFO800-957-7622 ext 102

[email protected]

CONTACT INFORMATION